Abstract:Background: Although neuregulin-1 (NRG1) fusions are known to be oncogenic drivers for lung cancer, chemotherapy is the major regimen for patients with advanced non-small-cell lung cancer (NSCLC). The efficacy and survival outcomes of pemetrexed-based treatments in patients with NRG1 fusion-positive NSCLC have not been established.Methods: We enrolled NSCLC patients with NRG1 fusions based on DNA/RNA-based next-generation sequencing (NGS). The study was conducted to determine the efficacy of treatment regimens in NRG1 fusion-positive advanced NSCLC patients. We also compared the survival outcomes among advanced NSCLC patients with different subtypes of NRG1 fusions.Results: A total of 42 advanced NSCLC patients with NRG1 fusions were enrolled. The subtypes of NRG1 fusions included CD74 (24/42 [57.1%]), which was the most common fusion partner, as well as other subtypes. Twenty-six patients were tested for PD-L1 expression, 24 of whom received a pemetrexed-based regimen as first-line treatment. Five patients received afatinib-targeted therapy. Of the patients who received pemetrexed-based chemotherapy, the median progression-free survival (PFS) was longer than patients who were not treated with pemetrexed-based chemotherapy (5.0 months vs. 2.5 months, P = 0.0279). Notably, among patients treated with afatinib, the overall response rate (ORR) was 40% (2/5) and the PFS was 3 months (95% confidence interval [CI], 0.853–5.147). No differences in median overall survival [OS] (21.0 months vs. 17.0 months, P = 0.6528) were observed between the pemetrexed-based chemotherapy and non-pemetrexed-based therapy groups. Significant differences in OS were detected among patients with different NRG1 fusion subtypes (P = 0.0373).Conclusions: Pemetrexed-based treatment could be effective in advanced NSCLC Chinese patients with NRG1 fusions. The development of more effective treatment strategies is worthy of further study for patients harboring NRG1 fusions.Funding Information: This study was granted by National Natural Science Foundation of China (81873277), the Zhejiang Chinese Medical Science and Technology Foundation (2021ZQ013), Xisike-Hanson Cancer Research Foundation (Y-HS2019-20), and Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation (HL-HS2020-5).Declaration of Interests: All authors declare no conflicts of interest.Ethics Approval Statement: Approval of the study protocol was obtained from Nanjing University of Chinese Medicine Institutional Review Board Committee (approval number: 2022NL-KS045). Individual consent for this retrospective analysis was waived.

NRG1 Fusions in NSCLC: Being eNRGy Conscious

Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

A Multicenter Study of NRG1 Fusions in Chinese Non-Small Cell Lung Cancer Patients and Response to Afatinib Using Next Generation Sequencing

Efficacy of Pemetrexed-Based Chemotherapy in Advanced NSCLC Chinese Patients with NRG1 Fusions by TNA Sequencing: A Multicenter Study

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Abstract 441: Functional Characterization of Recurrent CD74-NRG1 Fusions in Lung Adenocarcinoma

CD74-NRG1 Fusions in Lung Adenocarcinoma.

[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review]

Fluorescent in situ hybridization is a deceptive method for screening NRG1 gene rearrangements

Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.

Case report: High grade serous fallopian tube carcinoma with rare NRG1 gene fusion presenting as widespread peritoneal carcinomatosis

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D‐NRG1 gene fusion in prostate cancer by data‐drilling a de‐identified tumor database

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions

Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements

NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation

NTRK fusions in lung cancer: From biology to therapy

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer